REFRACTORY NON-HODGKIN LYMPHOMA

This study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study is testing whether combining two existing drugs—pembrolizumab and ATRA—can help control Hodgkin lymphoma or B-cell non-Hodgkin lymphoma that has returned or stopped responding to other treatments. It will enroll about 24 adults to see if the combination is safe and can…

This early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…

This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma that has returned or not responded to standard therapies. It will give 22 patients a three-part regimen: first a personalized cell therapy (CAR-T), followed by two other drugs. The main goal is …

This study is testing a new drug called tegavivint in children, teens, and young adults whose solid tumors or lymphomas have come back or haven't responded to other treatments. The main goals are to find the safest dose, understand the side effects, and see if the drug can help s…

This study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …

This study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…

This is the first study in people to test a new drug called HCB101 for advanced cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects in up to 80 adults with advanced solid tumors or non-Hodgkin lymphoma. Re…

This early-stage study is testing a personalized immune therapy called axicabtagene ciloleucel (a type of CAR-T) for people with HIV who have an aggressive form of B-cell lymphoma that has returned or not responded to prior treatments. The main goals are to check if the treatment…

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…